Arvinas Q4 revenue misses; names Randy Teel as CEO

Arvinas

24/02/2026 12:11

Overview

Biotech firm's Q4 revenue and net income missed analyst expectations

Company appointed Randy Teel, Ph.D., as new CEO

Company highlighted progress in clinical trials and pipeline developments

Outlook

Arvinas expects cash reserves to support operations into the second half of 2028

Company plans Phase 1 trial for ARV-6723 in mid-2026

Arvinas and Pfizer aim for vepdegestrant PDUFA action date on June 5, 2026

Result Drivers

CLINICAL TRIAL PROGRESS - Arvinas highlighted significant progress in its clinical trials, including the acceptance of ARV-102 data for an oral presentation at a major conference and the initiation of a first-in-human trial for ARV-027

R&D EXPENSES - Decrease in R&D expenses attributed to reduced personnel costs and external expenses, while continuing development of PROTAC drug candidates

PIPELINE DEVELOPMENTS - Arvinas emphasized the ongoing development of its PROTAC drug candidates, including ARV-806 and ARV-393, with notable preclinical and clinical advancements

Company press release: ID:nGNX1BKWLY

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$9.50 mln
$34.88 mln (13 Analysts)
Q4 Net Income
Miss
-$67.40 mln
-$40.62 mln (12 Analysts)
Q4 Operating income
Miss
-$74.60 mln
-$44.75 mln (14 Analysts)
Q4 Pretax Profit
Miss
-$67.20 mln
-$38.15 mln (12 Analysts)
Q4 Operating Expenses
$84.10 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)